Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6YSG3)

• Drug Name: LIQUIRTIGENIN Drug Info
• Synonyms: 578-86-9; 4',7-Dihydroxyflavanone; (S)-7-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one; (2S)-liquiritigenin; 5-DEOXYFLAVANONE; UNII-T194LKP9W6; 7-hydroxy-2-(4-hydroxy-phenyl)-chroman-4-one; T194LKP9W6; CHEMBL252642; CHEBI:28777; AK121923; (2S)-7-Hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (2S)-2-(4-hydroxyphenyl)-7-oxidanyl-2,3-dihydrochromen-4-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 114829
  ChEBI ID: CHEMBL252642
  CAS Number: CAS 578-86-9
  TTD Drug ID: DM6YSG3

Molecule-Related Drug Atlas

Drug(s) Targeting Aromatase (CYP19A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[4]
Letrozole	DMH07Y3	Estrogen-receptor positive breast cancer		Approved	[5]
Exemestane	DM9HPW3	Hormonally-responsive breast cancer	2C60-2C65	Approved	[5]
Aminoglutethimide	DMWFHMZ	Cushing disease	5A70	Approved	[6]
FADROZOLE	DM3C5GZ	Breast cancer	2C60-2C65	Approved	[7]
Testolactone	DMVY4GN	Breast cancer	2C60-2C65	Approved	[8]
LIAROZOLE	DM4OYXE	Dermatological disease	DA24.Y	Phase 2/3	[9]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[10]
BGS-649	DMO4MNQ	Endometriosis	GA10	Phase 2	[11]
NARINGENIN	DMHAZLM	N. A.	N. A.	Phase 1	[9]

Drug(s) Targeting Xanthine dehydrogenase/oxidase (XDH)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopurinol	DMLPAOB	Gout	FA25	Approved	[12]
Febuxostat	DMDEXQ0	Hyperuricaemia	5C55.Y	Approved	[13]
Fosdenopterin	DMR0TYK	Molybdenum cofactor deficiency	5B5K.A	Approved	[14]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[15]
Oxypurinol	DMURH4X	Heart failure	BD10-BD13	Phase 2/3	[16]
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[1]
Topiroxostat	DMA04DE	Gout	FA25	Phase 2	[17]
TMX-049	DME8PFQ	Diabetic nephropathy	GB61.Z	Phase 2	[18]
LC-350189	DMHT3CB	Gout	FA25	Phase 1	[19]
Azaindole derivative 5	DMD2BL3	N. A.	N. A.	Patented	[20]

Drug(s) Affected By Cytochrome P450 2C19 (CYP2C19)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[21]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[22]
Voriconazole	DMAOL2S	Aspergillosis	1F20	Approved	[23]
Chloramphenicol	DMFXEWT	Bacterial infection	1A00-1C4Z	Approved	[24]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[25]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[26]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[27]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[26]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[22]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[28]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Aromatase (CYP19A1)	TTSZLWK	CP19A_HUMAN	Inhibitor	[2]
Xanthine dehydrogenase/oxidase (XDH)	TT7RJY8	XDH_HUMAN	Inhibitor	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2C19 (CYP2C19)	OTFMJYYE	CP2CJ_HUMAN	Gene/Protein Processing	[3]

References

• [1] Inhibition of cow's milk xanthine oxidase by flavonoids. J Nat Prod. 1988 Mar-Apr;51(2):345-8.
• [2] Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
• [3] Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
• [4] Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
• [5] Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
• [6] Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
• [7] Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
• [8] Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
• [9] Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
• [10] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032111)
• [12] Allopurinol: xanthine oxidase inhibitor. Tex Med. 1966 Jan;62(1):100-1.
• [13] Clinical pipeline report, company report or official report of Takeda (2009).
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
• [15] Inhibition studies of bovine xanthine oxidase by luteolin, silibinin, quercetin, and curcumin. J Nat Prod. 2009 Apr;72(4):725-31.
• [16] Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988 Jan 15;37(2):349-52.
• [17] QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol. 2014 Apr;54(4):446-52.
• [18] Clinical pipeline report, company report or official report of Teijin Pharma.
• [19] Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects. Drug Des Devel Ther. 2015 Aug 31;9:5033-49.
• [20] An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015).Expert Opin Ther Pat. 2017 Mar;27(3):311-345.
• [21] Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
• [22] Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
• [23] The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
• [24] Cytochrome P450 inhibition potential of new psychoactive substances of the tryptamine class. Toxicol Lett. 2016 Jan 22;241:82-94.
• [25] Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
• [26] Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
• [27] Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
• [28] ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.